These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 19086875)

  • 1. Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence.
    Kamath J; Handratta V
    Expert Rev Neurother; 2008 Dec; 8(12):1787-97. PubMed ID: 19086875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Desvenlafaxine succinate: a newer antidepressant for the treatment of depression and somatic symptoms.
    Seo HJ; Sohi MS; Patkar AA; Masand PS; Pae CU
    Postgrad Med; 2010 Jan; 122(1):125-38. PubMed ID: 20107296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Desvenlafaxine: a new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder.
    Perry R; Cassagnol M
    Clin Ther; 2009 Jun; 31 Pt 1():1374-404. PubMed ID: 19698900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Desvenlafaxine in the treatment of major depressive disorder.
    Pae CU
    Expert Opin Pharmacother; 2011 Dec; 12(18):2923-8. PubMed ID: 22098230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician.
    Reddy S; Kane C; Pitrosky B; Musgnung J; Ninan PT; Guico-Pabia CJ
    Curr Med Res Opin; 2010 Jan; 26(1):139-50. PubMed ID: 19919295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Desvenlafaxine succinate for the treatment of major depressive disorder.
    Lohoff FW; Rickels K
    Expert Opin Pharmacother; 2008 Aug; 9(12):2129-36. PubMed ID: 18671467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Desvenlafaxine: another "me too" drug?
    Sopko MA; Ehret MJ; Grgas M
    Ann Pharmacother; 2008 Oct; 42(10):1439-46. PubMed ID: 18698015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Desvenlafaxine: a new antidepressant or just another one?
    Pae CU
    Expert Opin Pharmacother; 2009 Apr; 10(5):875-87. PubMed ID: 19351235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder.
    Montgomery SA; Fava M; Padmanabhan SK; Guico-Pabia CJ; Tourian KA
    Int Clin Psychopharmacol; 2009 Nov; 24(6):296-305. PubMed ID: 19779354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Desvenlafaxine in the treatment of major depressive disorder.
    Lourenco MT; Kennedy SH
    Neuropsychiatr Dis Treat; 2009; 5():127-36. PubMed ID: 19557107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Desvenlafaxine succinate for major depressive disorder.
    Sproule BA; Hazra M; Pollock BG
    Drugs Today (Barc); 2008 Jul; 44(7):475-87. PubMed ID: 18806899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the efficacy of desvenlafaxine for improving functioning and well-being outcome measures in patients with major depressive disorder: a pooled analysis of 9 double-blind, placebo-controlled, 8-week clinical trials.
    Soares CN; Kornstein SG; Thase ME; Jiang Q; Guico-Pabia CJ
    J Clin Psychiatry; 2009 Oct; 70(10):1365-71. PubMed ID: 19906341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial.
    Boyer P; Montgomery S; Lepola U; Germain JM; Brisard C; Ganguly R; Padmanabhan SK; Tourian KA
    Int Clin Psychopharmacol; 2008 Sep; 23(5):243-53. PubMed ID: 18703933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serotonin and Norepinephrine Reuptake Inhibitors.
    Shelton RC
    Handb Exp Pharmacol; 2019; 250():145-180. PubMed ID: 30838456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Duloxetine in the treatment of major psychiatric and neuropathic disorders.
    Müller N; Schennach R; Riedel M; Möller HJ
    Expert Rev Neurother; 2008 Apr; 8(4):527-36. PubMed ID: 18416656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Desvenlafaxine for the treatment of major depressive disorder.
    Kornstein SG; McIntyre RS; Thase ME; Boucher M
    Expert Opin Pharmacother; 2014 Jul; 15(10):1449-63. PubMed ID: 24914479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Desvenlafaxine for depression.
    Med Lett Drugs Ther; 2008 May; 50(1286):37-9. PubMed ID: 18487957
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system.
    Preskorn SH; Nichols AI; Paul J; Patroneva AL; Helzner EC; Guico-Pabia CJ
    J Psychiatr Pract; 2008 Nov; 14(6):368-78. PubMed ID: 19057238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Desvenlafaxine, a serotonin-norepinephrine uptake inhibitor for major depressive disorder, neuropathic pain and the vasomotor symptoms associated with menopause.
    Pae CU; Park MH; Marks DM; Han C; Patkar AA; Masand PS
    Curr Opin Investig Drugs; 2009 Jan; 10(1):75-90. PubMed ID: 19127490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Non-hormonal treatment for vasomotor symptoms during menopause: role of desvenlafaxine].
    Lilue M; Palacios S
    Ginecol Obstet Mex; 2009 Oct; 77(10):475-81. PubMed ID: 19902676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.